Ultragenyx Pharma (RARE) Tops Q2 EPS by 1c

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.72), $0.01 better than the analyst estimate of ($1.73).

Cash, cash equivalents, and investments were $457.5 million as of June 30, 2017.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Ultragenyx Pharma (RARE) PT Raised to $83 at Canaccord
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics